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Abstract
Background: Cardiovascular disease (CVD) is the primary cause of mortality and morbidity in Argentina
representing 34.2% of deaths and 12.6% of potential years of life lost (PYLL). The aim of the study was to estimate
the burden of acute coronary heart disease (CHD) and stroke and the cost-effectiveness of preventative
population-based and clinical interventions.
Methods: An epidemiological model was built incorporating prevalence and distribution of high blood pressure,
high cholesterol, hyperglycemia, overweight and obesity, smoking, and physical inactivity, obtained from the
Argentine Survey of Risk Factors dataset. Population Attributable Fraction (PAF) of each risk factor was estimated
using relative risks from international sources. Total fatal and non-fatal events, PYLL and Disability Adjusted Life
Years (DALY) were estimated. Costs of event were calculated from local utilization databases and expressed in
international dollars (I$). Incremental cost-effectiveness ratios (ICER) were estimated for six interventions: reducing
salt in bread, mass media campaign to promote tobacco cessation, pharmacological therapy of high blood
pressure, pharmacological therapy of high cholesterol, tobacco cessation therapy with bupropion, and a multidrug
strategy for people with an estimated absolute risk > 20% in 10 years.
Results: An estimated total of 611,635 DALY was lost due to acute CHD and stroke for 2005. Modifiable risk factors
explained 71.1% of DALY and more than 80% of events. Two interventions were cost-saving: lowering salt intake in
the population through reducing salt in bread and multidrug therapy targeted to persons with an absolute risk
above 20% in 10 years; three interventions had very acceptable ICERs: drug therapy for high blood pressure in
hypertensive patients not yet undergoing treatment (I$ 2,908 per DALY saved), mass media campaign to promote
tobacco cessation amongst smokers (I$ 3,186 per DALY saved), and lowering cholesterol with statin drug therapy
(I$ 14,432 per DALY saved); and one intervention was not found to be cost-effective: tobacco cessation with
bupropion (I$ 59,433 per DALY saved)
Conclusions: Most of the interventions selected were cost-saving or very cost-effective. This study aims to inform
policy makers on resource-allocation decisions to reduce the burden of CVD in Argentina.
Background
Chronic diseases are increasing in developing countries
and cardiovascular diseases account for 17.7 million
annual deaths around the world, constituting 11% of esti-
mates for the global burden of disease. It is estimated
that mortality due to coronary heart disease (CHD) and
stroke will increase by approximately 145% among men
and women from 1990 to 2020 in Latin America, com-
pared with a 28% increase for women and a 50% increase
for men over the same period in developed countries [1].
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account for more than 50% of the overall morbidity and
mortality. In fact, the age-adjusted mortality rate of car-
diovascular disease, including CHD and stroke was
206.4 per 100,000 (265.4 for men and 161.8 for women),
representing 34.2% of deaths and 12.6% of years of
potential life lost [2]. Adjusted mortality rates for non-
communicable diseases, as well as Potential Years of
Life Lost (PYLL) have declined steadily since 1987,
while mortality rates of communicable, maternal, perina-
tal and nutritional conditions have remained relatively
constant in the same 20-year period. Still, the adjusted
rate for non-communicable chronic diseases has been
five to six times the rate of communicable diseases in
Argentina, and the absolute number of deaths is increas-
ing due to the increasingly elderly population [3].
In common with many other Latin American coun-
tries, Argentina falls into an intermediate mortality
group where the main risk factors for disease are hyper-
tension, an elevated body mass index (BMI), alcohol
abuse and smoking [4]. Elevated BMI is due to excess
calories and insufficient activity, and a large proportion
of hypertension is due to these same lifestyle risks in
addition to a poor diet quality. Primary data describing
the prevalence and distribution of cardiovascular risk
factors in Argentina has recently been obtained through
two different population-based sources: the 2005 Minis-
try of Health National Risk Factor Survey [5]; and the
Cardiovascular Risk Factor Multiple Evaluation in Latin
America (CARMELA) [6]. There is strong evidence that
a 50% reduction in cardiovascular deaths can be attribu-
table to the reduction of just three modifiable risk fac-
tors, namely tobacco use, high blood pressure and
elevated cholesterol [7]. In Latin America, the majority
of cardiovascular risk could be explained by tobacco
use, abnormal lipids, abdominal obesity and high blood
pressure as shown in the recently published INTER-
HEART Latin American study [8]. Most cardiovascular
diseases are preventable and there is evidence that sup-
ports the effectiveness of interventions to reduce the
burden of cardiovascular disease through strategies that
reduce risk factors. Unfortunately, strategies to manage
cardiovascular conditions have been largely developed
for high-income countries which may not be affordable
to most of the developing world [9,10]. Although there
has been widespread recognition of the benefit of cost-
effectiveness evaluation to inform national health sys-
tems of priority settings, its potential has not been rea-
lized in the vast majority of countries, including
Argentina [11]. Nevertheless, cost-effective interventions
to prevent cardiovascular disease in developing countries
do exist, but have not been widely applied. Specifically,
population and community-based interventions appear
to be highly cost-effective when they reach large
populations, address high mortality and morbidity dis-
eases, and include multi-level integrated efforts. Inter-
ventions targeting individuals, especially high
cardiovascular risk subjects, are also cost-effective but
usually require clinical involvement and more resources.
Moreover, recent studies have consistently shown
the cost-effectiveness of interventions that lower
the burden of cardiovascular disease in developing
countries [12-14].
The aims of this study were 1) to develop an analytical
model to estimate the burden of acute CHD and stroke
attributable to modifiable cardiovascular disease risk fac-
tors in Argentina, 2) to explore the costs of major cardi-
ovascular events, and 3) to calculate the cost-
effectiveness of different population-based and clinical
interventions in order to inform local policy makers on
resource-allocation priority setting.
Methods
We conducted a population-level comparative risk
assessment for seven modifiable cardiovascular risk fac-
tors to be included in a model to assess their impact on
major cardiovascular events: acute myocardial infarction
(AMI), other non-infarction ischemic events and stroke.
We also estimated the individual and aggregate effect of
population-based and clinical interventions that might
modify the risks associated to these risk factors. These
interventions are supported by evidence in the literature
for clinical efficacy and population effectiveness esti-
mates that take into account detection and patient com-
pliance. Cardiovascular risk factors and interventions
were modeled for the adult population over 35 years old
since they are the usual target for most clinical interven-
tions. Finally, cardiovascular events, Disability Adjusted
Life Years (DALY) and interventions costs were derived.
Selection of Risk Factors
We selected specific risk factors that fulfilled the follow-
ing criteria: (1) Sufficient evidence was available on the
presence and magnitude of likely causal association with
CHD and stroke from high-quality epidemiological stu-
dies, (2) available interventions existed to modify asso-
ciated risk, (3) data on risk factor prevalence was
available from the First Argentinean Survey of Risk Fac-
tors (FASRF) or other nationally representative surveys
not subjected to selection bias.
The seven modifiable risk factors selected were: 1)
high blood pressure (HBP), 2) high cholesterol, 3) over-
weight and obesity, 4) elevated fasting glucose level and
type-2 diabetes mellitus, 4) tobacco smoking, 5) physical
inactivity,
Unfortunately, consumption of vegetables and fruits
was ill-defined in the FASRF since the daily quantity of
servings was not specified, for which we had to exclude
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dual dietary factors that would meet criteria for causal
effects, such as intake of trans fat, low marine omega-3
(seafood), and low polyunsaturated fat (exchanged for
saturated fat) were also excluded because of lack of reli-
able data on their respective prevalences, after a thor-
ough search of local surveys.
Data Sources
Risk Factors exposure
We obtained risk factor prevalence and distribution for
each individual enrolled in the FASRF is a nationally
representative survey including 41,393 subjects from all
districts of the country sampled through a probabilistic
multi-stage process [5]. The prevalence of risk factors was
obtained from self-reports obtained during an in-person
interview that was subsequently validated with direct mea-
sures in one district. For those subjects who reported not
to have ever measured her/his blood pressure (11.94%),
serum cholesterol (43.25%) or glycemia (23.49%) we con-
sidered them as not having the risk factor in the survey.
As this assumption could have underestimated their pre-
valence and population-attributable risk, we developed a
logistic regression model to estimate the odds and prob-
abilities for a subject with a certain demographic and risk
factor profile to have an abnormal value in each of these
three risk factors. These new set of risk factors prevalence
were used as an alternative scenario in the sensitivity ana-
lysis. STATA v8.0 was used to run these models.
Etiological effects of risk factors on disease-specific
mortality
We obtained the relative risk for CHD and stroke attri-
butable to each risk factor for each exposure category
(since all risks were measured in categories in the
FASRF), based on published observational studies, sys-
tematic reviews or meta-analyses of epidemiological stu-
dies. In previous observational studies used for effect
sizes, the majority had adjusted for potential confound-
ing factors. Each relative risk used in our analysis repre-
sents the best judgment of the evidence for the effect of
risk factor exposure on disease-specific mortality. The
etiological effect sizes along different age-strata and gen-
der are shown in Table 1.
Disease-specific deaths
The number of deaths by CHD (ICD-10 codes I20×, I24×
and I25× for non-infarction ischemic events and I21×
and I22× for AMI) and stroke (ICD-10 codes I60-I61,
I63-I64) were obtained from the National Directorate of
Health Statistics of the Argentine Ministry of Health [15].
Estimating mortality and disability attributable to risk
factors
For each risk factor and for each disease causally asso-
ciated with its exposure, we computed the proportional
reduction in disease-specific deaths that would occur if
risk factor prevalence had been reduced to zero. This is
known as the population-attributable risk (PAR) and
measures the total effects of a risk factor (direct as well
as mediated through other factors). In order to estimate
the PAR of each risk factor, we developed an epidemio-
logical simulation model in Microsoft Excel(r), contain-
ing the prevalence and distribution of risk factors
according to each age and sex strata as observed in the
F A S R F[ 5 ] .I nt h i sw a y ,t h i sm a t r i xo f4 1 , 3 9 2r e g i s t r i e s
from the FASRF, representing the Argentine population,
was split into all possible combinations of risk factors.
Additional risk for each combination was assumed to be
the product (multiplication) of the relative risk of the
risk factors involved [16]. Finally, the baseline absolute
risks for both fatal and non-fatal events for people with-
out any of the selected risk factors were derived consid-
ering the overall risk, prevalence and additional risk
associated to each combination. The global risk of death
(across all combinations and age groups) was calibrated
against the overall number of deaths due to CHD and
stroke corresponding to Argentina in the year 2005 [15].
Finally, the number of non-fatal events for each death
from CHD and stroke was extrapolated using the lethal-
ity rate from the Public Hospital registry corresponding
to the year 2000 [17].
In addition to the estimation of the prevalence of
cardiovascular risk factors and their associated relative
risk, the spreadsheet contained the cost and disutility
associated with each event in order to obtain a deter-
ministic estimate of the burden of disease, expressed in
DALY and overall costs. A DALY is a summary mea-
sure that combines years of life lost due to premature
death and years of life lived with disability [18]. One
DALY can be thought of as one lost year of healthy
life. DALYs were calculated based on the model devel-
oped by Murray et al. [9].
The duration of disability was estimated by using the
software DISMOD II [19]. Disability weights were
obtained from two Australian studies on burden of dis-
ease [20,21]. For the calculation of years of life lost due
to premature death, we used a life expectancy at birth
of 80 and 82.5 for men and women, respectively, as
recommended for global comparisons in the Global Bur-
den of Disease study [9]. Finally, years of life lost due to
premature death were obtained from National death
registries and years of life lived with disability were
obtained by multiplying the estimated number of non-
fatal events by each disability weight, for each age gen-
der strata [19].
In order to estimate the PAR associated to each risk
factor, a new estimation of deaths, non fatal events,
DALY and costs of CHD and stroke were calculated.
These estimations were obtained multiplying the basal
Rubinstein et al. BMC Public Health 2010, 10:627
http://www.biomedcentral.com/1471-2458/10/627
Page 3 of 15absolute risk by the product of the relative risks involved
in each combination stratum, assuming a relative risk
equal to 1 for the index risk factor, weighted by its
respective prevalence. Overall deaths, non fatal events,
DALY and costs between the estimation for Argentina in
2005 and the new estimation without the index risk fac-
tor, was assumed to be the PAR attributable to that parti-
cular risk factor. We programmed a macro using Python
language [22], in which we performed 1,000 iterations of
the prevalence for each combination of risk factors
assuming a binomial distribution. Therefore, a new abso-
lute risk was obtained in each iteration, and new estima-
tions of total deaths, non fatal events, DALY and costs
were obtained. Finally, we used the empirical PAR distri-
bution to estimate the 95% confidence interval (95%CI)
using the percentile method.
Table 1 List of relative risks included into the model
Age groups
18-39 40-44 45-59 60-64 65-69 70-79 80+ Reference
Relative risk for coronary heart disease
High blood pressure (m) 1.3 2.0 2.2 2.7 2.7 2.7 2.2 [83-85]
High blood pressure (w) 2.5 2.5 2.2 2.7 2.7 2.7 2.2 [83-85]
High glycemia (m) 2.0 2.0 2.0 2.0 2.0 2.0 2.0 [86]
High glycemia (w) 2.5 2.5 2.5 2.5 2.5 2.5 2.5 [86]
Overweight (m) 1.2 1.2 1.2 1.2 1.2 1.2 1.2 [87]
Overweight (w) 1.2 1.2 1.2 1.2 1.2 1.2 1.2 [87]
Obesity (m) 1.5 3.0 3.0 3.0 1.5 1.5 1.5 [87]
Obesity (w) 1.5 1.5 1.5 1.5 1.5 1.5 1.5 [87]
High cholesterol (m) 2.0 2.0 2.0 2.0 2.0 2.0 2.0 [8]
High cholesterol (w) 3.4 3.4 3.4 3.4 3.4 3.4 3.4 [8]
Current smoker (m) 2.4 2.4 2.4 1.8 1.8 1.7 1.4 [88]
Current smoker (w) 2.2 2.2 2.4 2.1 2.1 1.7 1.3 [88]
Former smoker (m) 1.3 1.3 1.3 1.3 1.2 1.2 1.2 [89]
Former smoker (w) 1.6 1.6 1.6 1.6 1.2 1.2 1.2 [89]
Non-sedentary life style (m) 0.7 0.7 0.7 0.7 0.7 0.7 0.7 [8]
Non-sedentary life style (w) 0.7 0.7 0.7 0.7 0.7 0.7 0.7 [8]
Relative risk for stroke
High blood pressure (m) 3.0 3.0 2.9 2.4 2.4 2.1 1.5 [83]
High blood pressure (w) 2.4 2.4 2.2 2.1 2.1 1.9 1.5 [83]
High glycemia (m) 2.0 2.0 2.0 2.0 2.0 2.0 2.0 [86]
High glycemia (w) 2.0 2.0 2.0 2.0 2.0 2.0 2.0 [86]
Overweight (m) 1.2 1.2 1.2 1.2 1.2 1.2 1.2 [87]
Overweight (w) 1.1 1.1 1.1 1.1 1.1 1.1 1.1 [87]
Obesity (m) 1.6 1.6 1.6 1.6 1.6 1.6 1.6 [90]
Obesity (w) 1.3 1.3 1.3 1.3 1.3 1.3 1.3 [90]
High cholesterol (m) 1.2 1.2 1.2 1.2 1.2 1.2 1.2 [91]
High cholesterol (w) 1.2 1.2 1.2 1.2 1.2 1.2 1.2 [91]
Current smoker (m) 2.4 2.4 2.4 1.8 1.8 1.7 1.4 [88]
Current smoker (w) 2.2 2.2 2.2 2.1 2.1 1.7 1.3 [88]
Former smoker (m) 1.0 1.0 1.0 1.0 1.0 1.0 1.0 [89]
Former smoker (w) 1.3 1.3 1.3 1.3 1.0 1.0 1.0 [89]
Non-sedentary life style (m) 0.8 0.8 0.8 0.8 0.8 0.8 0.8 [92]
Non-sedentary life style (w) 0.8 0.8 0.8 0.8 0.8 0.8 0.8 [92]
m: men; w: women.
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Different population-based and clinical interventions to
reduce cardiovascular disease burden were explored con-
sidering not only the evidence of efficacy and effectiveness
[23] but also the feasibility to be implemented in Argen-
tina. Relative risk reductions of the interventions were
adjusted by population effectiveness measures taking into
account target population coverage as well as patient com-
pliance. All interventions have a time horizon of 5 years
after which maximum population effectiveness is assumed.
The evidence about population effectiveness of mass
media campaign targeted to the promotion of physical
activity [24-27], salt reduction in food [28,29], control of
overweight and obesity [30-35], and promotion of healthy
habits [36,37] was non-conclusive, and hence these inter-
ventions were not included in the model. On the other
hand, evidence on the effectiveness of media campaigns
against smoking was generally strong and local programs
had already been implemented [38-42]. Efficacy of inter-
ventions were modeled as a relative risk reduction or by a
reduction on risk factor prevalence. Effect sizes and joint
effect of interventions used in the analysis were based on
systematic reviews of randomized trials and meta-analysis,
when possible. Intervention effects with their correspond-
ing relative risks estimates are shown in Table 2.
Population based-interventions
Lowering salt intake in the population through redu-
cing salt in bread A program involving the cooperation
between the Government, consumer associations and
the Bakery Chambers in an effort to reduce 1 gram of
salt per 100 grams of bread. Argentina has an average
individual consumption of 12 grams of salt per day, 3.4
grams coming from bread. Local experiences showed
that it is possible to reduce the amount of salt in bread
without being detected as less palatable. At present,
there is a pilot training program implemented in
selected cities in Argentina to make bakers reduce salt
in bread by using special salt dispensers [43]. This inter-
vention could imply a population-wide reduction of 1.33
mmHg of systolic blood pressure per person and 1% of
the PAR of CHD and stroke [28,29,44].
Mass Media Campaign to promote tobacco cessation
This program of the National Ministry of Health
involves an annual campaign through four TV spots, six
radio spots and written material in major newspapers,
magazines and public spaces. Costs were retrieved from
data from previous campaigns of the National Ministry
of Health. This intervention would reduce the preva-
lence of smoking by 7% [38-42,45].
Individual (clinical) interventions
Treatment of high blood pressure Interventions
involved lifestyle change promotion and pharmacological
therapy to achieve blood pressure control (SBP/DBP less
than 140/90). Target population was composed of adults
over 35 years old with the diagnosis of high blood pres-
sure and no treatment (over 1.3 millions of Argentine
population representing 8.2% people older than 35 years
old), estimating for this intervention a relative risk
reduction of 44% for CHD and 49% for stroke [13]. We
assumed that 40% of the population would take one
drug, 40% two drugs and 20% three or more drugs. The
drugs and daily doses evaluated were hydrochlorothia-
zide (25 mg), atenolol (50 mg), enalapril (10 mg), and
amlodipine (10 mg), and the treatment mix was 50% of
the population taking thiazides, 20% atenolol, 20%
angiotensin-converting enzyme inhibitor and 10% amlo-
dipine [46]. The same efficacy for each drug category
was also assumed. Analysis indicated that these inter-
ventions, with a 50% rate of disease detection and 50%
drug compliance as indicated by the Canadian Hyper-
tension Guidelines [47], would reduce PAR of cardiovas-
cular disease and stroke by 8%.
Table 2 Effectiveness of selected interventions
Intervention Efficacy References
Population based interventions
Mass Media Campaign promote tobacco cessation Reduction of current smoker
prevalence: 7%
[38-42,45]
Reducing salt in bread RR: 0.99 [28,29]
Clinical interventions
Bupropion treatment for tobacco cessation Annual cessation rate: 28%. [49,50]
Pharmacological high blood pressure treatment* For CHD: RR = 0.66
For stroke: RR = 0.51
[13]
Pharmacological high cholesterol treatment with atorvastatin For CHD: RR = 0.77
For stroke: RR = 0.81
[13,55]
Treatment with four drugs (Polypill strategy) for people with an absolute cardiovascular risk of
more than 20% at 10 years
For CHD: RR = 0.34
For stroke: RR = 0.32
[12,13,53-55]
CHD: Coronary Heart Disease, RR: relative risk.
* Include: atenolol, enalapril, amlodipine and hidroclorothiazide.
** Include: aspirine, enalapril, amlodipine and atorvastatin.
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involved promotion of low-cholesterol diet and use of
statins (atorvastatin 10 mg, 20 mg and 40 mg for 50%,
40% and 10% of the target population, respectively),
according to local estimates and assumptions. Target
population was adults over 35 years old with high choles-
terol and no treatment (almost one million people repre-
senting 5.2% of people older than 35 years old).
Achieving a cholesterol target of less than 240 mg/dl, (6.2
mm/l) would provide an estimated reduction of 8% of the
PAR of CHD and stroke with a 50% detection and 50%
drug compliance rate according to ATP III [48].
Tobacco cessation therapy Motivational interventions
from health professionals and drug therapy with bupro-
pion for a 2-month period (300 mg per day) would
result in an estimated reduction of 4% of the PAR of
CHD and stroke [49]. In most studies with bupropion
for tobacco cessation, the annual quitting rate of smo-
kers was 28% vs. 12%, as compared to placebo [50,51].
According to a recent national survey of tobacco preva-
lence, only 11% of total smokers in Argentina were will-
ing to quit smoking and therefore were considered the
target population for this intervention [52]. According
to these estimates, the spontaneous annual cessation
rate would be 1.32% (12% of the 11% of smokers willing
to quit) that would raise to 3.08% with bupropion (28%
× 11%), since we would expect a prevalence reduction
of 1.76% (3.08%-1.32%).
Treatment based on a population absolute risk
approach (Polypill strategy) Since the “Polypill” is not
yet in Argentine markets, we designed a pharmacologi-
cal therapy with 4 pills (hydrochlorothiazide 25 mg, ena-
lapril 10 mg, atorvastatin 10 mg and aspirin 100 mg),
prescribed to people older than 35 years old with an
estimated combined risk of a cardiovascular event over
the next decade above 20%, based on the data from the
FASRF. This intervention would imply a relative risk
reduction of CHD of 66% (RR = 0.34) and of stroke of
68% (RR = 0.32) [12,13,53-55].
Assuming that at least 50% of the target population is
reached by the intervention, a 50% patient compliance
rate with treatment for this group, and 70% of provider
compliance due to a presumed raised awareness of risks
for both subjects, the Polypill strategy would result in a
population effectiveness of 17,5%. Relative risks for
CHD and stroke for individuals from this high-risk sub-
group were estimated by using the beta coefficients
from the Framingham Heart Study [16].
Estimating costs of acute cardiovascular events and
interventions
Costs of acute events
Cost categories (i.e. inpatient hospital days, doctor visits,
tests, drugs and ancillary services, and diagnostic and
therapeutic procedures) for AMI, other non-infarction
ischemic events such as unstable angina and stroke were
first identified. For each event the quantities and unit
prices of inputs were retrieved from hospital databases
and other local sources [56-66], as well as expert opi-
nion when necessary. The quantities of each input iden-
tified were assessed and multiplied by the unit price of
each item to obtain the unit cost of each resource.
Finally, the total cost of the acute event resulted from
the addition of all of the identified consumed resources
in each category.
Costs of interventions
Costs included program-level expenses associated with
management of the interventions (i.e. administration,
training and information, dissemination by multiple
media sources) and patient-level costs (i.e. primary care
visits, ancillary tests and drugs). The quantities of each
input required were assessed and multiplied by the unit
price of each input for the 5 year intervention imple-
mentation period. The quantity of patient-level resource
inputs for each intervention (i.e. inpatient hospital days,
doctor visits, tests, drugs) were identified from local or
international published data if available or expert opi-
nion should the former not be available. Costs of drugs
were calculated using a mix of blood pressure lowering
drugs composed of 50% hydrochlorothiazide, 20% ateno-
lol, 20% enalapril and 10% amlodipine, according to a
published local study [46]. Cost of blood pressure lower-
ing drugs, atorvastatin and bupropion as well as other
input costs and expense data were extracted from local
sources [65-67]. Other cost data were obtained from the
Health Care Costs Database from the Institute of Clini-
cal Effectiveness and Health Policy [62]. A list of costs
and sources of the interventions and selected health
events is depicted in Table 3.
Cost of clinical interventions included, in addition to
their specific costs of visits, tests and drugs, 290 coun-
trywide training workshops on cardiovascular risk detec-
tion, assessment and control targeted to 8,639 general
practitioners from the public and private health sector,
along the 5 year period of the intervention, with peri-
odic boosters through email and postal mail. Except
when explicitly stated, costs related to labor, equipment,
capital, overhead or joint costs were regarded as exist-
ing, ongoing, or common to all interventions and there-
fore were excluded in the calculation. We also excluded
costs of accessing health interventions that would
include the resources used by patients and their families
to obtain an intervention (transport costs) as well as
productivity gains or losses, as the study was conducted
from a purchaser perspective. All costs were calculated
in Argentine pesos for the year 2007, requiring in some
cases the use of Health and General CPI to adjust for
annual inflation, and finally converted and expressed
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ity conversion rate AR$ 1.55 = 1 I$ [68]. The discount-
ing of long term costs was performed at a 3% rate.
Perspective
Since Argentina’s healthcare system consists of a multi-
tier system divided in three large sectors: public, social
security and private, we incorporated the perspective of
the whole Argentine healthcare system as a purchaser of
health services.
Calculating cost-effectiveness of interventions
Cost-effectiveness analysis considers the costs and
effects of adding new interventions to current practice
or the cost of replacing an existing intervention with
another targeting the same condition. In order to esti-
mate the reduction in disease burden related to the
reduction of cardiovascular disease, we built a model to
predict the burden associated with specific diseases or
risk factors to develop disease. We calculated the effect
of interventions in our model, assuming that all reduced
the relative risk associated with the presence of each
cardiovascular risk factor. In the case the effect of the
intervention was a reduction of the prevalence (i.e.:
tobacco cessation), a new relative risk was estimated as
a proportional combination of the relative risk asso-
ciated with the risk factor (for the proportion of people
that were still smokers) and the relative risk of those
that no longer had that risk factor (i.e.: former smokers).
Finally, the model translated these changes into a new
estimation of cardiovascular events, overall costs and
DALY lost, specific for age and sex. This estimation was
then compared to the estimation without the interven-
tion. In addition, the annual cost of the intervention was
imputed for the year analyzed. For each intervention,
the Incremental Cost-Effectiveness Ratio (ICER) of the
interventions compared to no intervention was mea-
sured as cost per averted DALY. Effect sizes and joint
effect of interventions used in the analysis were based
on systematic reviews of randomized trials and meta-
analysis, when possible.
To translate changes in the risk of age and sex specific
cardiovascular disease events into changes in population
health quantified in terms of DALY, we used a standard
methodology described elsewhere [69].
There is no universal criterion that defines a threshold
cost-effectiveness ratio, above which an intervention
would not be considered cost-effective. We chose to use
guidelines specifically intended for international compar-
isons, as proposed by the Commission on Macroeco-
nomics and Health, which defines interventions with an
ICER that is less than three times Gross Domestic Pro-
duct per capita as a “cost-effective” intervention and as
“very cost-effective” if ICER is less than the GDP per
capita [70,71]. Argentina’s GDP per person in 2007 was
estimated in I$ 13,255.09 [72].
Uncertainty and sensitivity analysis
We also did a probabilistic, multivariate sensitivity ana-
lysis using Monte Carlo simulation [73,74] of 1,000 ran-
domly selected sets of variables, to assess the effects of
uncertainty in the prevalence of risk factors, population
attributable risk and effect sizes of interventions. In
addition, an undiscounted scenario was considered for
costs and DALY, and a non age-weighted scenario was
also analyzed for DALY.
Results
We estimated a lethality rate of 11.9% in men and 18%
in women; and 17.4% in men and 18.9% in women, for
CHD and stroke, respectively [17]. According to these
estimates, about 263,025 annual acute CHD and stroke
events would be expected, representing an annual cost
of I$ 1,036,506,958. More than 60% of total events and
costs are accounted by men. Table 4 shows the estima-
tion of the overall number of annual cardiovascular
events in Argentina, burden of disease and costs of
events. As observed, more than 600,000 DALYs and
almost 400,000 YPLL were lost in 2005 due to CHD
and stroke.
Burden of Disease attributable to modifiable
cardiovascular Risk Factors
Population attributable risks, costs of events and DALY
lost to cardiovascular disease for the overall risk factors
and for each single modifiable risk factor selected, can
Table 3 Interventions and related health events summary
costs
Event cost per hospital admission 2007 I$
Coronary Heart Disease 4,245.39
Stroke 3,455.48
Population-based interventions
Mass Media Campaign promote tobacco cessation* 3,164,785.75
Reducing salt in bread
† 193,576.23
Individual interventions (yearly cost per person‡)
Pharmacological high blood pressure treatment 49.72
Pharmacological high cholesterol treatment 118.79
Bupropion treatment for tobacco cessation 117,15
Modified Polypill strategy 103.46
I$: international dollars. PPP conversion rate (2007) 1.55 Argentinean peso = 1
I$,
* Ten years duration of campaign, with discounting (3% annual rate).
† Assuming 54 meeting of 30 bakers each (around 800-600 bakers), with
discounting (3% annual rate).
‡ Includes health center visits, drug and lab test costs. Programmatic costs
were not included (I$ 1,194,067.52).
Note: Cost of blood pressure lowering drugs, atorvastatin and bupropion as
well as other input costs and charges data were extracted from local sources
[65-67]. Other cost data were obtained from the Health Care Costs Database
by the Institute of Clinical Effectiveness and Health Policy [62].
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Page 7 of 15be seen in Tables 5 and 6, respectively. All risk factors
together explained 75% of fatal and non-fatal acute
CHD and stroke events, 82,4% of acute CHD events
(84.0% in women) and 62.4% of strokes (66,6% in men).
Similarly, modifiable risk factors explained 75,5% of
costs of acute events and 70.7% of DALY lost. The most
important single risk factor was high BP, explaining 37%
of all CHD and strokes and one-third of all DALY lost
in 2005. The rest of the risk factors have similar attribu-
table burden in term of CV events, ranging between
13,9% (high glycemia) to 18,1% (physical inactivity). (see
Table 6).
Cost-effectiveness of selected interventions
Table 7 summarizes the results of economic evaluation
of the 6 distinct interventions giving their total annual
costs and costs per beneficiary, health effects in terms of
DALY averted (non age-weighted and 3% discounted),
percent of DALY saved due to cardiovascular disease
and average cost-effectiveness ratio for each in I$ per
DALY averted. Two interventions were cost-saving: low-
ering salt intake in the population through reducing salt
in bread and treatment targeted to persons with an
absolute risk above 20% in 10 years (modified polypill
strategy). Moreover, the implementation of the polypill
strategy was also associated with almost a 2% decrease
in DALY lost to cardiovascular disease. On the other
hand, the impact of reducing salt in bread was more
limited (0.11% of decrease of DALY lost) due in part to
the lower extension and magnitude of this intervention.
Two interventions had very acceptable ICER: 1) drug
therapy for high blood pressure in hypertensive patients
not yet under going treatment with an ICER of I$ 2,908
per DALY saved and an annual reduction of 2.3% of
cardiovascular disease burden; and 2) mass media cam-
paign to promote tobacco cessation amongst smokers,
with an ICER of I$ 3,186 per DALY saved (0.11% of car-
diovascular disease burden). An additional intervention,
lowering cholesterol with statins (I$ 14,432 per DALY
saved), was considered cost-effective according to the
guidelines mentioned above. Finally, one intervention,
tobacco cessation with bupropion (I$ 59,433 per DALY
saved) was not found to be cost-effective. This is in part
because bupropion is much more expensive than blood
pressure lowering drugs and also because, as it is not
currently covered in the public sector, the government
does not usually exert its purchasing power to get lower
prices. Following local surveys, we assumed that only
11% of the population of smokers would be willing to
quit smoking each year and consequently start on a pro-
gram, the population impact of tobacco cessation ther-
apy was much smaller than expected.
Figure 1 shows the ICER of the six distinct interven-
tions along the cost effectiveness plane with their
Table 4 Estimation of total cases, costs and burden of
disease of acute CHD and stroke
Men Women Total
Total AMI events [%] 62,132
[72.1%]
24,031
[27.9%]
86,163
[100.0%]
Total non-infarction events [%] 51,660
[68.5%]
23,751
[31.5%]
75,411
[100.0%]
Total stroke events [%] 53,432
[52.7%]
48,018
[47.3%]
101,450
[100.0%]
Total events [%] 167,225
[63.6%]
95,800
[36.4%]
263,025
[100.0%]
Total costs* I$ [%] 667,728,147
[64.4%]
368,778,811
[35.6%]
1,036,506,958
[100.0%]
Total DALY† [%] 293,419
[48.0%]
318,217
[52.0%]
611,635
[100.0%]
Total PYLL‡ [%] 218,547
[55.5%]
175,617
[44.6%]
394,163
[100.0%]
95%CI: 95% confidence interval, AMI: acute myocardial infarction, DALY:
disability-adjusted life years, I$: international dollars, PYLL: Potential Years of
Life Lost.
* Only direct medical costs by hospitalization were considered. Costs are
measured in 2007 international dollars (I$).
† With discounting (3% annual rate), without age weight.
‡ With discounting (3% annual rate).
Table 5 Proportional Burden of Disease and costs attributable to all cardiovascular risk factors potentially modifiable
Population-attributable Fraction % (95%CI)
Men Women Total
Total AMI events (both fatal and non-fatal) 81.8 (81.3-82.2) 84.1 (82.8-85.0) 82.4 (81.9-82.8)
Total non-infarction events (both fatal and non-fatal) 81.5 (80.9-82.0) 83.5 (81.9-84.7) 82.1 (81.5-82.6)
Total stroke events (both fatal and non-fatal) 66.6 (65.7-67.4) 57.6 (56.4-58.8) 62.4 (61.6-63.1)
Total events (both fatal and non-fatal) 76.8 (76.2-77.4) 70.7 (69.4-71.7) 74.6 (74.0-75.1)
Total costs* 77.5 (76.9-78.0) 72.0 (70.7-73.1) 75.5 (75.0-76.0)
Total DALY
† 76.0 (75.5-76.4) 65.8 (65.0-66.5) 70.7 (70.2-71.1)
Total PYLL
‡ 76.5 (75.9-76.9) 69.6 (68.6-70.5) 73.4 (72.9-73.9)
Results of 1,000 iterations, both sexes.
95%CI: 95% confidence interval, AMI: acute myocardial infarction, DALY: disability-adjusted life years, PYLL: Potential Years of Life Lost.
* Only direct medical costs by hospitalization were considered.
† With discounting (3% annual rate), without age weight.
‡ With discounting (3% annual rate).
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responds to the cost-saving interventions.
Sensitivity Analyses
We examined the effect of a change in the PAR estimate
of the overall risk factors selected along a reasonable
range of probabilities, by creating alternative scenarios
with different prevalence and distributions of risk fac-
tors. We also explored undiscounted and age-weighted
DALY as compared to the base case scenario with
DALY discounted at 3 percent and non age-weighted.
In all circumstances, the ranking as well as the magni-
tude of each intervention remained the same. Finally,
the results of the probabilistic sensitivity analyses to
estimate the uncertainty surrounding the central esti-
mates of each intervention is expressed through the 95%
CI showed in Table 7.
Discussion
Our study analyzed the FASRF at individual level to esti-
mate the burden of cardiovascular disease in Argentina
attributable to modifiable risk factors in order to
Table 6 Proportional Burden of Disease and costs attributable to each cardiovascular risk factor potentially modifiable
Population-attributable Fraction % (95%CI)
Both sexes Tobacco use Overweight
and Obesity
High Blood
pressure
High
cholesterol
High glycemia Physical
inactivity
Total AMI events (both
fatal and non-fatal)
22.5 (22.2 - 22.8) 20.9 (20.4 - 21.3) 38.5 (37.9 - 39.1) 25.1 (24.4 - 25.8) 13.9 (13.2 - 14.5) 20.9 (20.6 - 21.2)
Total non-infarction events
(both fatal and non-fatal)
18.5 (18.1 - 18.8) 18.6 (18.2 - 19.0) 40.9 (40.1 - 41.5) 26.2 (25.2 - 27.0) 14.8 (14.0 - 15.6) 21.6 (21.2 - 22.0)
Total stroke events (both
fatal and non-fatal)
10.8 (10.5 - 11.2) 11.7 (11.3 - 12.0) 32.7 (32.0 - 33.3) 5.8 (5.6 - 6.1) 13.2 (12.3 - 14.0) 13.0 (12.7 - 13.3)
Total events (both fatal
and non-fatal)
16.9 (16.5 - 17.2) 16.7 (16.3 - 17.0) 37.0 (36.3 - 37.5) 18.0 (17.4 - 18.5) 13.9 (13.1 - 14.6) 18.1 (17.7 - 18.3)
Total costs* 17.3 (17.0 - 17.6) 17.1 (16.7 - 17.4) 37.3 (36.6 - 37.9) 18.9 (18.3 - 19.5) 13.9 (13.2 - 14.7) 18.4 (18.1 - 18.7)
Total DALY
† 16.1 (15.7 - 16.4) 13.8 (13.5 - 14.0) 36.6 (36.1 - 37.0) 13.4 (13.0 - 13.7) 13.6 (13.0 - 14.2) 15.5 (15.2 - 15.7)
Total PYLL
‡ 16.6 (16.3 - 16.9) 15.1 (14.8 - 15.4) 37.5 (36.9 - 38.0) 16.6 (16.1 - 17.1) 13.9 (13.2 - 14.6) 16.9 (16.6 - 17.1)
Men Tobacco use Overweight
and Obesity
High Blood
pressure
High
cholesterol
High glycemia Physical
inactivity
Total AMI events (both
fatal and non-fatal)
26.7 (26.2 - 27.1) 24.7 (24.1 - 25.2) 37.0 (36.4 - 37.6) 19.0 (18.3 - 19.6) 12.4 (11.8 - 13.0) 20.2 (19.8 - 20.6)
Total non-infarction events
(both fatal and non-fatal)
23.1 (22.6 - 23.5) 22.3 (21.8 - 22.8) 40.1 (39.3 - 40.8) 19.3 (18.6 - 20.0) 13.5 (12.8 - 14.2) 20.6 (20.2 - 21.2)
Total stroke events (both
fatal and non-fatal)
14.2 (13.7 - 14.7) 16.7 (16.0 - 17.3) 35.2 (34.3 - 36.0) 5.2 (4.9 - 5.5) 13.5 (12.6 - 14.4) 12.2 (11.7 - 12.6)
Total events (both fatal
and non-fatal)
21.6 (21.1 - 22.0) 21.4 (20.9 - 21.9) 37.4 (36.7 - 38.1) 14.7 (14.1 - 15.2) 13.1 (12.4 - 13.8) 17.8 (17.4 - 18.2)
Total costs* 22.0 (21.6 - 22.5) 21.7 (21.2 - 22.2) 37.6 (36.8 - 38.2) 15.2 (14.7 - 15.8) 13.1 (12.4 - 13.8) 18.1 (17.7 - 18.6)
Total DALY
† 22.1 (21.6 - 22.6) 20.5 (20.1 - 20.9) 38.7 (38.1 - 39.3) 12.1 (11.7 - 12.6) 13.0 (12.3 - 13.7) 15.6 (15.3 - 16.0)
Total PYLL
‡ 21.6 (21.1 - 22.1) 20.7 (20.2 - 21.1) 38.7 (38.1 - 39.3) 13.4 (12.9 - 13.8) 13.1 (12.4 - 13.8) 16.5 (16.2 - 16.9)
Women Tobacco use Overweight
and Obesity
High Blood
pressure
High
cholesterol
High glycemia Physical
inactivity
Total AMI events (both
fatal and non-fatal)
11.9 (11.5 - 12.3) 11.0 (10.5 - 11.6) 42.4 (41.1 - 43.5) 41.0 (39.2 - 42.7) 17.7 (16.2 - 19.1) 22.6 (22.2 - 23.1)
Total non-infarction events
(both fatal and non-fatal)
8.5 (8.0 - 9.0) 10.5 (9.9 - 11.2) 42.5 (40.7 - 44.0) 41.1 (38.4 - 43.1) 17.7 (15.8 - 19.6) 23.7 (23.1 - 24.2)
Total stroke events (both
fatal and non-fatal)
7.1 (6.8 - 7.6) 6.1 (5.8 - 6.5) 29.9 (28.9 - 30.8) 6.6 (6.1 - 7.1) 12.8 (11.5 - 14.2) 14.0 (13.6 - 14.3)
Total events (both fatal
and non-fatal)
8.6 (8.3 - 9.1) 8.4 (8.0 - 8.9) 36.2 (34.9 - 37.3) 23.8 (22.4 - 24.9) 15.2 (13.8 - 16.8) 18.6 (18.1 - 19.0)
Total costs* 8.8 (8.4 - 9.3) 8.7 (8.2 - 9.7) 36.8 (35.5 - 37.9) 25.5 (24.1 - 26.7) 15.5 (14.0 - 17.0) 19.0 (18.6 - 19.5)
Total DALY
† 10.5 (10.1 - 10.9) 7.6 (7.3 - 7.9) 34.5 (33.8 - 35.2) 14.5 (13.9 - 15.1) 14.1 (13.2 - 15.1) 15.3 (15.0 - 15.6)
Total PYLL
‡ 10.4 (10.0 - 10.8) 8.3 (7.9 - 8.7) 36.0 (35.0 - 36.9) 20.7 (19.7 - 21.6) 14.8 (13.6 - 16.0) 17.3 (16.9 - 17.6)
Results of 1000 iterations, basal case, both sexes.
95%CI: 95% confidence interval, AMI: acute myocardial infarction, DALY: disability-adjusted life years, PYLL: Potential Years of Life Lost.
* Only direct medical costs by hospitalization were considered.
† With discounting (3% annual rate), without age weight.
‡ With discounting (3% annual rate).
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Page 9 of 15model the impact of some preventive interventions to
reducing this burden, as well as estimating their cost-
effectiveness. Based on our data, the PAR of all the
risk factors analyzed explained more than 75% of the
acute CHD events and strokes in men and women.
Only high blood pressure explained more than one-
third of the events while each one of the other risk
factors explained between 14% and 18%. WHO
recently addressed the importance of chronic disease
prevention as a neglected health issue in LMIC;
achievement of the global goal to reduce chronic dis-
ease death rates by 2% every year would avert 36 mil-
lion deaths between 2005 and 2015 [75,76]. Achieving
this target would also save almost 10% of the expected
Table 7 Cost effectiveness analysis of selected interventions
Intervention Total costs Net Total costs * DALY saved † Percent of
DALY saved
ICER per DALY
saved ‡
I$ I$ DALY (95%CI) % (95%CI) I$ (95%CI)
Reducing salt in bread 193,576.23 -946,580.87 672.80 0.11% -1,406.93
(-) (-) (-) (-) (-)
Treatment targeted to persons with an absolute risk
above 20% in 10 years (polypill strategy
23,489,613.55 -2,979,727.10 12,108.15 1.98% -246.45
(22,002,839.35 -
24,877,996.13)
(-3,663,248.39-
-2,301,924.52)
(11,396.45-
12,752.71)
(1.86% -
2.09%)
(-307.74 -
-189.68)
Pharmacological therapy for high blood pressure 62,251,491.82 41,014,269.81 14,100.16 2.31% 2,908.86
(61,201,512.65 -
63,303,292.70)
(40,070,763.64 -
42,021,481.43)
(13,919.53 -
14,275.31)
(2.28% -
2.33%)
(2,841.81 -
2,977.48)
Mass Media Campaign to promote tobacco cessation 3,164,785.75 2,053,674.53 644.73 0.11% 3,186.71
(-) (2,012,812.78 -
2,090,361.57)
(624.52 -
666.90)
(0.10% -
0.11%)
(3,024.42 -
3,337.92)
Pharmacological therapy of high cholesterol 92,751,189.47 81,762,199.07 5,666.16 0.93% 14,431.46
(90,559,448.95 -
94,981,610.94)
(79,775,242.39 -
83,805,632.99)
(5,507.87 -
5,824.03)
(0.90% -
0.95%)
(14,077.55 -
14,809.92)
Therapy with Bupropion for 51,778,301.95 50,318,932.00 846.80 0.14% 59,433.02
tobacco cessation (50,792,163.89 -
52,752,733.57)
(49,372,843.67 -
51,286,965.18)
(820.26 -
875.93)
(0.13% -
0.14%)
(57,819.14 -
60,906.25)
95%CI: 95% confidence interval, I$: international dollars - PPP conversion rate (2007) 1.55 Argentinean peso = 1 I$, DALY: disability adjusted life years, ICER:
incremental cost-effectiveness ratio. The ICERs express the results of 1,000 iterations.
* Net Total costs are calculated as Total costs minus the corresponding averted event costs. All costs are measured in 2007 International dollars (I$).
‡ Derived from bootstrapping techniques.
Figure 1 Interventions along the cost-effectiveness plane. Costs are expressed in International dollars (I$, 2007).
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Page 10 of 15loss in national income in these settings [7]. Consider-
ing the growing burden of cardiovascular disease and
costs in developing countries, especially for transitional
countries like Argentina, this study is critical to pro-
vide local decision-makers with information about car-
diovascular disease burden. Furthermore, by comparing
the relative costs and health effects of interventions for
preventing cardiovascular disease, we can focus policy
debate concerning the trade-offs or opportunity costs
of financing one intervention over another.
Establishing the cost-effectiveness of preventive inter-
ventions for cardiovascular disease in developing coun-
try contexts is not straightforward, due to both the
paucity of existing evidence, and because there is no
universally agreed threshold for considering the cost-
effectiveness of an intervention to be ‘too high’ or
‘right’. What is acceptable to health and finance deci-
sion-makers depends largely on the country context.
The Disease Control Priorities Project (DCPP), has iden-
tified several chronic disease interventions as cost-effective
at a cost of below US$1,000 per DALY [77]. However,
the affordability of interventions will vary significantly
across countries, even among a group of interventions
believed to be cost-effective in the global sense. More-
over, sensitivity analysis done as part of the cost effec-
tiveness analysis modeling for the DCPP showed that
the cost-effectiveness of public education campaigns at
the population level could be very good or far less
favorable depending on how much it cost to reach peo-
ple using a reasonable range of costs. In addition, even
a very inexpensive intervention might not be worth
implementing if it targets a chronic disease with low
prevalence in a given country or region.
In an earlier analysis, Murray et al. [12] modeled
selected population-based and individual health inter-
ventions to lower high blood pressure and high choles-
terol in the epidemiological contexts of developing
countries. The authors found that all interventions were
highly cost-effective in the sub-region of the Americas
to which Argentina belongs.
More recently, Asaria et al., assessed the financial
costs and health effects of a voluntary reduction in the
salt content of processed foods by manufacturers plus a
mass media campaign to encourage dietary change in 23
selected low and middle income countries, including
Argentina. They estimated that a 15% reduction in diet-
ary salt intake in Argentina would save 60,000 lives over
the period 2006-2015 at a cost of US$ 0.14 per capita
(equivalent to AR$ 16.7 million for a population of
Argentina (38 millions in 2005) [38].
As compared to these previous studies [12,38], our
intervention to decrease salt intake in bread was cost-
saving, although both our health impact and cost esti-
mates were appreciably lower than those summarized
above, partly because we only included a series of one-
off meetings with bread makers from large cities, and
also because we used a lower effect size.
In regards to the intervention oriented to reduce high
blood pressure and high cholesterol our ICER were
remarkably higher than those reported by Murray et al.
[12]. The causes of this apparent discrepancy are two-
fold: firstly, the counterfactual scenario designed by
Murray, based on the WHO-CHOICE methodology [71]
entails lifting the constraints of the current mix of inter-
ventions, using a null scenario of no costs and no inter-
ventions as a starting point, as opposed to our
assumption that almost half of Argentine population
were already receiving treatment; based on the data of
the FASRF; and secondly, our cost estimates are consid-
erably higher, which reflects the fact that key interven-
tion resource inputs in Argentina (including human
resources, secondary care and drugs) are much more
expensive than the regional average. The addition of
individual-level interventions with a multi-drug regimen
on the basis of opportunistic contact with the health
service, as reported by Gaziano et al. [78], has been esti-
mated at US$ 2.93 per capita in a country like Argen-
tina, but would save a further 50,000 lives over a
10-year period.
Our analyses have shown that the multidrug regimen
of four highly effective drugs (polypill strategy, with an
annual cost of I$ 101 or I$ 32 per capita in 2007) could
lead to cost-saving prevention and treatment for sub-
jects with an absolute risk above 20% in 10 years, with
2% of reduction in DALY lost to cardiovascular disease
even considering a population effectiveness of less than
20% the potential targeted population. Other treatment
cutpoints for this intervention, where ICERs would likely
be far higher, were not evaluated, including subjects
with lesser CV risk or subjects over age 55 as originally
proposed by Wald and Law (53), The study of Gaziano
et al about the cost-effectiveness of the Polypill regimen
[13] modeled an ICER of less than US$ 900 for a similar
risk population in the Latin American region.
According to the threshold adopted by World Health
Organization, an intervention that saves one DALY for
less than three times the gross domestic product (GDP)
per capita is considered cost-effective, while one that
s a v e saD A L Yf o rl e s st h a no n eG D Pp e rc a p i t ai s
deemed very cost-effective [71]. As Argentina’s GDP per
person in 2007 was I$13,255 (US$ 6,644) [79,80], esti-
mated ICER of all interventions analyzed except tobacco
cessation with bupropion (I$ 59,433 per DALY saved)
fell well within the ‘very cost-effective’ or cost-effective
category. In fact, two interventions - reducing salt intake
in bread and the absolute risk approach therapy with
four drugs - were cost-saving. In an earlier study of
cost-effectiveness of cardiovascular interventions in
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nario of no costs and no interventions, most of our
interventions were very cost-effective [81]. Should we
have used a counterfactual scenario based on what the
public health sector was actually spending on the care
of cardiovascular disease we would have obtained much
lower ICER or even cost-saving interventions like we
have found in this study.
In addition, the potential budget impact of the imple-
mentation of the four cost saving or cost-effective inter-
ventions mentioned above was in the range of I$ 194
million in 2005. This expenditure would be partly offset
by the savings obtained through avoided cardiovascular
acute events. Moreover, the financing of these interven-
tions, even considering low population effectiveness
according to our conservative scenario, could reduce at
least 7% the cardiovascular disease burden with its con-
sequent health, economic and social impact.
Some limitations of the present work are important to
be acknowledged. 1), the risk factors included in the
model were limited to those that were specifically
addressed in the national survey as they were specifi-
cally defined. In this regard, concerning the intake of
fruits and vegetables, we were bound to the two defined
options as posed in the specific question of the survey:
more or less than five servings a week (rather than
more or less than five servings a day), which is clearly
inappropriate based on WHO recommendations [82].
This limitation prompted us to exclude this risk factor
for further analysis. Other risk factors related to diet
such as trans fat, low marine omega-3, and low polyun-
saturated fat were also excluded due to lack of popula-
tion based data stressing the importance of obtaining
future national-level data on these and other dietary
risk factors for future analysis; 2) since the prevalence
of risk factors was obtained from self-reports of partici-
p a n t sa n dn o tf r o md i r e c tm e a s u r e s ,t h e yw e r ed e f i n e d
dichotomously or categorically (as having or not having
the risk factor) for the calculation of the PAR. This
implies that the risk of a particular risk factor behaves
like an “all or none” phenomenon, which is obviously
not true given the continuous nature of this risk in all
of the selected risk factors. In this regard, estimating
the theoretical minimum risk exposure distribution
would be a more appropriate method should this had
been possible; 3) we have just modeled interventions
that either had been tested in pilot studies (i.e.: reducing
salt in bread) or were considered key data to model the
intervention (i.e.: just 11% of total smokers in Argentina
as potential quitters to model the impact of tobacco
cessation with bupropion); 4), we did nor model poten-
tial side effects of the multidrug intervention. Ignoring
side effects in the analysis could overestimate the ICER
of the polypill strategy. 5) our study does not assume
any benefit from the pharmacological interventions in
the population that is already receiving treatment, as if
they were appropriately controlled, which is not true.
No matter that this is aligned with our conservative
estimates, the ICER of high blood pressure or high cho-
lesterol therapy look less attractive in terms of reduc-
tion of disease burden or cost-effectiveness; 6) as in all
modeling studies, our study synthesized data from many
sources and used several assumptions in the design of
the model. As real life decision making tools, these
types of model-based studies are explicit analyses to
help health priority setting, and are not a “search of the
ultimate truth"; and 7) some inputs, as it is also com-
monplace in modeling studies, were derived from inter-
national sources. This was done mainly with relative
measures such as relative risks of different cardiovascu-
lar risk factors, or relative effects of interventions, which
o nt h eo t h e rh a n d ,a r ew i d e l yt h o u g h tt ob em o r eg e n -
eralizable from setting to setting.
Conclusions
Overall, evidence exists to conclude that there are
important clinical as well as economic consequences of
cardiovascular disease, consequences that are not only
important to the individual and his/her family but also
to the economy at large. At the same time, there are
severe gaps in the evidence that call for more research
into the avoidable burden of cardiovascular disease, in
particular for developing countries. Despite the increas-
ing burden of cardiovascular disease in Argentina, rank-
ing first over the last decades as a cause of mortality
and morbidity, national health programs and policies are
still focused on interventions aimed to tackle commu-
nicable diseases or perinatal or childhood conditions,
overlooking actions and programs targeted to lifestyle
and nutritional changes in the population at large or
pharmacological interventions to reduce cardiovascular
disease burden in high risk people.
In conclusion, most of the interventions selected were
cost-saving or very cost-effective according to WHO
standards. Moreover, the financing of these interven-
tions could reduce at least 5% the cardiovascular disease
burden with its consequent health, economic and social
impact. This study aims to inform policy makers on
resource-allocation decisions to reduce the burden of
CVD, especially for middle-income developing countries
like Argentina.
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